Our Mission:
To better understand how hormones, cytokines, and metabolites regulate body weight, nutrient metabolism, and cancer growth; and how these factors are changed with dietary interventions.
We are a physician-scientist laboratory studying how tumors rewire whole-body metabolism, and how diet can be used as therapy. We work across mouse physiology, human cohorts, and clinical trials.
Recent work:
JAK1/2 inhibition delays cachexia and improves survival by restoring appetite. Ruxolitinib extends survival in mice with lung cancer, and the benefit runs through increased food intake rather than a direct effect on muscle, which reframes how JAK inhibitors should be tested in patients. bioRxiv, 2025. Led by Ezequiel Dantas. https://doi.org/10.1101/2025.10.21.683287
Intestinal fructose metabolism drives fat absorption and synergizes with GLP-1 receptor agonists. Fructose handling in the small intestine promotes the absorption of unsaturated fat, and blocking it amplifies the weight loss produced by GLP-1 receptor agonism, pointing to a combination strategy for obesity. bioRxiv, 2026. Led by Carolina EcheverrÃa. https://doi.org/10.64898/2026.06.03.729910
High pyruvate kinase activity kills BRCA2-deficient tumors. Forcing pyruvate kinase activity upward is selectively lethal to tumors that have lost BRCA2, identifying a metabolic vulnerability in a genetically defined cancer. Under review. Led by Maira Di Tano. Pre-print coming soon.
Recent News and Updates:
